Literature DB >> 10731627

Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake.

P Popoli1, R Reggio, A Pèzzola.   

Abstract

In unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats, a rodent model of Parkinson's disease (PD), the adenosine A(2A) receptor antagonist SCH 58261 significantly increased (+180%, p <.01) the number of rotations induced by a low dose of quinpirole (a dopamine D(2) receptor agonist), while it did not significantly modify the effects of a comparably low dose of SKF 38393 (a dopamine D(1) receptor agonist). The dose-dependent potentiating effects of SCH 58261 on quinpirole-induced turning were similar in caffeine-treated rats (1 g/l in drinking water over 14 days) and control animals (tap water). The selective potentiating effects of SCH 58261 on D(2)-dependent turning confirm the existence of a potent and specific A(2A)/D(2) receptor-receptor interaction. The persistence of the potentiating effects of SCH 58261 after chronic caffeine intake suggests that no tolerance should develop towards the antiparkinsonian effects of adenosine A(2A) receptor antagonists with chronic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731627     DOI: 10.1016/S0893-133X(99)00144-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  14 in total

Review 1.  Presynaptic modulation controlling neuronal excitability and epileptogenesis: role of kainate, adenosine and neuropeptide Y receptors.

Authors:  João O Malva; Ana P Silva; Rodrigo A Cunha
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

Review 2.  Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Authors:  Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2016-01-20       Impact factor: 4.530

3.  Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.

Authors:  Kathrin Sichardt; Karen Nieber
Journal:  Purinergic Signal       Date:  2007-09-05       Impact factor: 3.765

Review 4.  Caffeine and the control of cerebral hemodynamics.

Authors:  Dale A Pelligrino; Hao-Liang Xu; Francesco Vetri
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.

Authors:  In-Young Choi; Jae-Chul Lee; Chung Ju; Sunyoung Hwang; Geum-Sil Cho; Hyuk Woo Lee; Won Jun Choi; Lak Shin Jeong; Won-Ki Kim
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

6.  Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum.

Authors:  William F Schwindinger; Lauren J Murphree Mihalcik; Kathryn E Giger; Kelly S Betz; Anna Maria Stauffer; Joel Linden; Denis Herve; Janet D Robishaw
Journal:  J Biol Chem       Date:  2010-07-16       Impact factor: 5.157

7.  Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.

Authors:  Seung-Nam Kim; Ah-Reum Doo; Ji-Yeun Park; Hyunwoo J Choo; Insop Shim; Jongbae J Park; Younbyoung Chae; Bena Lee; Hyejung Lee; Hi-Joon Park
Journal:  Brain Res       Date:  2013-12-07       Impact factor: 3.252

Review 8.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

Review 9.  Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease.

Authors:  Emmanuelle Pourcher; Philippe Huot
Journal:  Mov Disord Clin Pract       Date:  2015-07-25

Review 10.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.